Leukemia, Acute Lymphoblastic Clinical Trial
Official title:
A Treatment Study Protocol of the ALLTogether Consortium for Infants, Children and Young Adults (0-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL): a Pilot Study
The pilot study collects the experience of previously successful treatment of infants, children and young adults, with ALL from a number of well-renowned study groups into a new platform protocol, which is both a comprehensive system for stratification and treatment of ALL in this age-group as well as the basis for several randomised trials included in the study-design. The pilot study is implemented as a master protocol without study specific interventions, thus as an observational study. The pilot study is for countries/study-groups who intend to join ALLTogether1 (including experimental interventions). For these countries the pilot study is crucial to optimise diagnostics, registration systems, collaborations with vendors, logistics and data-checks before starting the main study. The study only includes "standard of care" treatment included in the master protocol.
Status | Recruiting |
Enrollment | 500 |
Est. completion date | August 2030 |
Est. primary completion date | August 2028 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 0 Years to 45 Years |
Eligibility | Inclusion Criteria: - Patients newly diagnosed with T-lymphoblastic (T-cell) or B-lymphoblastic precursor (BCP) leukaemia (ALL) according to the WHO-classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition 2017) and with a diagnosis confirmed by an accredited laboratory at a participating paediatric oncology or adult haematology centre. - Age 0 - < 46 years (one day before 46th birthday) at the time of diagnosis, with the exception of infants with KMT2A-r BCP ALL (see exclusion criteria below). - Patients with surface immunoglobulin negative (sIG-) BCP-ALL and an IG::MYC rearrangement, unless they have a concurrent BCL2/6 rearrangement. T-ALL patients with MYC translocations. - Informed consent signed by the patient and/or parents/legal guardians according to country-specific age related guidelines - The ALL diagnosis should be confirmed by an accredited laboratory at a participating paediatric oncology or adult haematology centre. - The patient should be diagnosed and treated at a participating paediatric oncology or adult haematology centre in the participating countries. - The patient should be a resident in one of the participating countries on a permanent basis or should intend to settle in a participating country, for instance by an application for asylum. Patients who are visiting the country as tourists should not be included. However, returning expatriots and patients who intend to stay at least for the duration of the treatment with primary diagnosis abroad may be included if no treatment has been administered and the diagnostic procedures are repeated at a participating centre. - All women of childbearing potential (WOCBP) have to have a negative pregnancy test within 2 weeks prior to the start of treatment. Exclusion Criteria: - Age < 365 days and KMT2A-rearranged (KMT2A-r) BCP-ALL (documented presence of a KMT2A-split by FISH and/or a KMT2A fusion transcript). These patients will be transferred to an appropriate trial for infant KMT2A-r BCP-ALL, if available. - Age >45 years at diagnosis. - Patients with a previous malignant diagnosis (ALL as a second malignant neoplasm - SMN). - Relapse of ALL. - Patients with mature B-ALL (as defined by surface IG positivity) or any patients with IG::MYC and a concurrent BCL2/6 rearrangement. - Patients with Ph-positive ALL (documented presence of t(9;22)(q34;q11) and/or of the BCR::ABL1 fusion transcript). These patients will be transferred to an appropriate trial for t(9;22) if available. - Previously known ALL prone syndromes (e.g. Li-Fraumeni syndrome, germline ETV6 mutation), except for Down syndrome. Exploration for such ALL prone syndromes is not mandatory and patients in whom genetic work-up reveals a new germ-line mutation (index-cases) will remain in the study. - Treatment with systemic corticosteroids (>10mg/m2/day) for more than one week and/or other chemotherapeutic agents in a 4-week interval prior to diagnosis (pre-treatment). - Pre-existing contraindications to any treatment according to the ALLTogether protocol (constitutional or acquired disease prior to the diagnosis of ALL preventing adequate treatment). - Any other disease or condition, as determined by the investigator, which could interfere with the participation in the study according to the study protocol, or with the ability of the patients to cooperate and comply with the study procedures. - Women of childbearing potential who are pregnant at the time of diagnosis. - Women of childbearing potential and fertile men who are sexually active and are unwilling to use adequate contraception during therapy. Efficient birth control is required, see section 17.8. - Female patients, who are breast-feeding. - Essential data missing from the registration of characteristics at diagnosis (in consultation with the protocol chair). |
Country | Name | City | State |
---|---|---|---|
Denmark | Aalborg University Hospital, Dept of Paediatrics | Aalborg | |
Denmark | Aarhus University Hospital | Aarhus | |
Denmark | Aarhus University Hospital, Child and Adolescent Health | Aarhus | |
Denmark | Rigshospitalet, Dept of Haematology | Copenhagen | |
Denmark | Rigshospitalet, Dept of Paediatrics | Copenhagen | |
Denmark | Odense University Hospital, Dept of Paediatrics | Odense | |
Estonia | North Estonia Medical Centre, Dept of Haematology | Tallinn | |
Estonia | Tallinn Children´s Hospital, Dept of Paediatrics | Tallinn | |
Estonia | Tartu University Hospital | Tartu | |
Finland | Helsinki University Hospital, Dept of Haematology | Helsinki | |
Finland | Helsinki University Hospital, Dept of Paediatrics | Helsinki | |
Finland | Kuopio University Hospital, Dept of Haematology | Kuopio | |
Finland | Kuopio University Hospital, Dept of Paediatrics | Kuopio | |
Finland | Oulu University Hospital, Dept of Haematology, Dept of Medicine | Oulu | |
Finland | Oulu University Hospital, Dept of Paediatrics | Oulu | |
Finland | Tampere University Hospital, Dept of Haematology | Tampere | |
Finland | Tampere University Hospital, Dept of Paediatrics | Tampere | |
Finland | Turku University Hospital, Clinical Haematology and Stem Cell Transplantation Unit | Turku | |
Finland | Turku University Hospital, Dept of Paediatrics | Turku | |
Iceland | Landspitali University Hospital, Children's Hospital | Reykjavík | |
Lithuania | Children's Hospital, Affiliate of Vilnius University Hospital | Vilnius | |
Lithuania | Vilnius University Hospital | Vilnius | |
Norway | Haukeland University Hospital, Dept of Haematology | Bergen | |
Norway | Haukeland University Hospital, Dept of Paediatrics | Bergen | |
Norway | Oslo University Hospital, Dept of Haematology | Oslo | |
Norway | Oslo University Hospital, Dept of paediatric haemato- and oncology | Oslo | |
Norway | Stavanger University Hospital, Dept of Haematology | Stavanger | |
Norway | University Hospital North Norway, Dept of Haematology | Tromsø | |
Norway | University Hospital of North Norway, Dept of Paediatrics | Tromsø | |
Norway | St. Olavs University Hospital, Dept of Haematology | Trondheim | |
Norway | St. Olavs University Hospital, Dept of Paediatrics | Trondheim | |
Spain | Hospital Universitario San Joan de Déu | Barcelona | |
Spain | Hospital Infantil Universitario Nino Jesus | Madrid | |
Sweden | Sahlgrenska University Hospital, Dept of Paediatric Haematology and Oncology | Gothenburg | |
Sweden | Sahlgrenska University Hospital, Section for Haematology and coagulation | Gothenburg | |
Sweden | Linköping University Hospital, Dept of Haematology | Linköping | |
Sweden | Linköping University Hospital, Dept of Paediatrics | Linköping | |
Sweden | Skåne University Hospital, Dept of Haematology | Lund | |
Sweden | Skåne University Hospital, Dept of Paediatrics | Lund | |
Sweden | Örebro University Hospital, Section for Haematology | Örebro | |
Sweden | Karolinska University Hospital, Dept of Paediatric Oncology and Haematology | Stockholm | |
Sweden | Karolinska University Hospital, Patient area Haematology | Stockholm | |
Sweden | Norrland University Hospital, Dept of Haematology | Umeå | |
Sweden | Norrland University Hospital, Dept of Paediatrics | Umeå | |
Sweden | Uppsala University Hospital, Dept of Haematology | Uppsala | |
Sweden | Uppsala University Hospital, Dept of Paediatric Haematology and Oncology | Uppsala |
Lead Sponsor | Collaborator |
---|---|
Mats Heyman | NordForsk, Nordic Society for Pediatric Hematology and Oncology, The Swedish Childhood Cancer Foundation |
Denmark, Estonia, Finland, Iceland, Lithuania, Norway, Spain, Sweden,
Mondelaers V, Suciu S, De Moerloose B, Ferster A, Mazingue F, Plat G, Yakouben K, Uyttebroeck A, Lutz P, Costa V, Sirvent N, Plouvier E, Munzer M, Poiree M, Minckes O, Millot F, Plantaz D, Maes P, Hoyoux C, Cave H, Rohrlich P, Bertrand Y, Benoit Y; Children-s Leukemia Group (CLG) of the European Organization for Research and Treatment of Cancer (EORTC). Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951. Haematologica. 2017 Oct;102(10):1727-1738. doi: 10.3324/haematol.2017.165845. Epub 2017 Jul 27. — View Citation
Pieters R, de Groot-Kruseman H, Van der Velden V, Fiocco M, van den Berg H, de Bont E, Egeler RM, Hoogerbrugge P, Kaspers G, Van der Schoot E, De Haas V, Van Dongen J. Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group. J Clin Oncol. 2016 Aug 1;34(22):2591-601. doi: 10.1200/JCO.2015.64.6364. Epub 2016 Jun 6. — View Citation
Schramm F, Zimmermann M, Jorch N, Pekrun A, Borkhardt A, Imschweiler T, Christiansen H, Faber J, Feuchtinger T, Schmid I, Beron G, Horstmann MA, Escherich G. Daunorubicin during delayed intensification decreases the incidence of infectious complications - a randomized comparison in trial CoALL 08-09. Leuk Lymphoma. 2019 Jan;60(1):60-68. doi: 10.1080/10428194.2018.1473575. Epub 2018 Jul 3. — View Citation
Toft N, Birgens H, Abrahamsson J, Griskevicius L, Hallbook H, Heyman M, Klausen TW, Jonsson OG, Palk K, Pruunsild K, Quist-Paulsen P, Vaitkeviciene G, Vettenranta K, Asberg A, Frandsen TL, Marquart HV, Madsen HO, Noren-Nystrom U, Schmiegelow K. Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia. 2018 Mar;32(3):606-615. doi: 10.1038/leu.2017.265. Epub 2017 Aug 18. — View Citation
Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R, Rowntree C, Richards S. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013 Mar;14(3):199-209. doi: 10.1016/S1470-2045(12)70600-9. Epub 2013 Feb 7. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Event-free survival (EFS) compared to historical controls | 5 year | ||
Primary | Overall survival (OS) compared to historical controls | 5 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Unknown status |
NCT02360930 -
Vincristine PK and PD in the AYA Population Compared to Younger Children
|
N/A | |
Recruiting |
NCT05306301 -
Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients
|
Phase 2 | |
Not yet recruiting |
NCT06101381 -
CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma
|
Phase 1/Phase 2 | |
Terminated |
NCT02935543 -
CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL
|
Phase 2 | |
Active, not recruiting |
NCT05440409 -
CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL
|
||
Completed |
NCT02393859 -
Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)
|
Phase 3 | |
Completed |
NCT05064787 -
Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy
|
N/A | |
Terminated |
NCT02435550 -
iCare for Cancer Patients
|
N/A | |
Completed |
NCT02799147 -
GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia
|
Phase 1/Phase 2 | |
Terminated |
NCT02580981 -
Acute Lymphoblastic Leukemia Therapies Informed by Genomic Analyses
|
N/A | |
Recruiting |
NCT04307576 -
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
|
Phase 3 | |
Completed |
NCT04942730 -
Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)
|
Phase 2 | |
Terminated |
NCT01761682 -
Acute Lymphoblastic Leukemia Registry at Asan Medical Center
|
||
Completed |
NCT04327037 -
Safety of Expanded Haploidentical Natural Killer Cells for Leukemia
|
Phase 1 | |
Terminated |
NCT02349178 -
Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT
|
Phase 2 | |
Recruiting |
NCT04209244 -
Effect of Fish Oil on Hyperlipidemia and Toxicities in Children and Young Adults With Acute Lymphoblastic Leukemia
|
N/A | |
No longer available |
NCT00590915 -
Erwinase Master Treatment Protocol
|
N/A |